Abstract
Subclinical hypercortisolemia is the most common secretory function disorder of the adrenal glands caused by the presence of adenoma or hyperplasia of the adrenal cortex. The primary hormonal test performed in the diagnosis of an incidentaloma is a test with 1 mg of dexamethasone. Lack of cortisol suppression after taking 1 mg of dexamethasone is a screening test for hypercortisolemia. Depending on the clinical symptoms, we are able to distinguish between overt and subclinical forms of cortisol excess. Subclinical hypercortisolemia does not cause somatic features of Cushing's syndrome.
However, even a slight excess of cortisol has been found to significantly increases cardiovascular risk, prevalence of osteoporosis with vertebral fractures and impairs glucose tolerance. In patients with subclinical hypercortisolemia, there are no determined criteria to define strict indications for adrenalectomy. There are many studies showing the beneficial effect of resection of the adrenal adenoma producing cortisol, which led to a reduction in blood pressure and an improvement in the metabolic profile in patients. However, these positive changes do not apply to all patients. As a result, the current European recommendations refer to surgical treatment only when pharmacological treatment fails to achieve good control of hypertension, glucose metabolism or weight reduction.
Some authors believe that not only the adrenal gland tumor may be a cause of the metabolic syndrome, but on the other hand, the hyperinsulinism causes adrenal hyperplasia and excessive secretion of cortisol. In every clinical case, the surgery indication should be carefully analyzed. Primary management is the implementation of pharmacological treatment, regular physical activity and an appropriate diet.
References
(1) Chiodini I. Diagnosis and Treatment of Subclinical Hypercortisolism. J Clin Endocrinol Metab 2011; 96(5):1223-1236. DOI:10.1210/jc.2010-2722.
(2) Terzolo M, Bovio S, Reimondo G, et al. Subclinical Cushing’s syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am 2005; 34:423-439 DOI:10.1016/j.ecl.2005.01.008.
(3) Reincke M. Subclinical Cushing’s syndrome. Endocrinol Metab Clin North Am 2000; 29:47-56. DOI:10.1016/s0889-8529 (05)70115-8.
(4) Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 2006; 29:298-302. DOI:10.1007/BF03344099.
(5) Nawar R, Aron D. Adrenal incidentalomas – a continuing management dilemma. Endocr Relat Cancer 2005; 12:585-598. DOI:10.1677/erc.1.00951.
(6) Terzolo M, Reimondo G, Bovio S, et al. Subclinical Cushing’s syndrome. Pituitary 2004; 7:217-223. DOI:10.1007/s11102-005-4024-6.
(7) Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526-1540. DOI:10.1210/jc.2008-0125.
(8) Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 2000; 85:1440-1448. DOI:10.1210/jcem.85.4.6515.
(9) Kasperlik-Załuska A, Rosłonowska E, Słowinska-Srzednicka J, et al. Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol (Oxf) 1997; 46:29-37 DOI:10.1046/j.1365-2265.1997.d01-1751.x.
(10) Kasperlik-Załuska A, Otto M, Cichocki A, et al. Incidentally discovered adrenal tumors: a lesson from observation of 1,444 patients. Horm Metab Res 2008; 40(5):338-341. DOI:10.1055/s-2008-1073167.
(11) Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab 2000; 85:637-644. DOI:10.1210/jcem.85.2.6372.
(12) Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175(2):G1-G34. DOI:10.1530/EJE-16-0467.
(13) Tsagarakis S, Roboti C, Kokkoris P, et al. Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas. Clin Endocrinol (Oxf) 1998; 49:165-171. DOI:10.1046/j.1365-2265.1998.00509.x.
(14) Morelli V, Masserini B, Salcuni AS, et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf) 2010, 73:161-166. DOI:10.1111/j.1365-2265.2010.03794.x.
(15) Nunes ML, Vattaut S, Corcuff JB, et al. Late-night salivary cortisol for diagnosis of overt and subclinical Cushing’s syndrome in hospitalized and ambulatory patients. J Clin Endocrinol Metab 2009; 94:456-462. DOI:10.1210/jc.2008-1542.
(16) Masserini B, Morelli V, Bergamaschi S, et al. The limited role of midnight salivary cortisol in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentalomas. Eur J Endocrinol 2009; 160:87-92. DOI:10.1530/EJE-08-0485.
(17) Yanase T, Oki Y, Katabami T, et al. New diagnostic criteria of adrenal subclinical Cushing's syndrome: opinion from the Japan Endocrine Society. Endocr J 2018; 65(4):383-393. DOI:10.1507/endocrj.EJ17-0456.
(18) Contreras LN, Cardoso E, Lozano MP, et al. Detection of preclinical Cushing’s syndrome in overweight type 2 diabetic patients. Medicina (B Aires) 2000; 60:326-330.
(19) Reimondo G, Pia A, Allasino B et al. Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin Endocrinol (Oxf) 2007; 67:225-229. DOI:10.1111/j.1365-2265.2007.02865.x.
(20) Park J, De Luca A, Dutton H, et al. Cardiovascular Outcomes in Autonomous Cortisol Secretion and Nonfunctioning Adrenal Adenoma: A Systematic Review. J Endocr Soc 2019; 3(5):996-1008. DOI:10.1210/js.2019-00090.
(21) Kageyama K, Oki Y, Nigawara T, et al. Pathophysiology and treatment of subclinical Cushing's disease and pituitary silent corticotroph adenomas [Review]. Daimon 2014; 61(10):941-948. DOI:10.1507/endocrj.ej14-0120.
(22) Garrapa GG, Pantanetti P, Arnaldi G, et al. Body composition and metabolic features in women with adrenal incidentaloma or Cushing’s syndrome. J Clin Endocrinol Metab 2001; 86:5301-5306. DOI:10.1210/jcem.86.11.8059.
(23) Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol 2014; 2(5):396-405. DOI:10.1016/S2213-8587(13)70211-0.
(24) Debono M, Harrison RF, Chadarevian R, et al. Resetting the Abnormal Circadian Cortisol Rhythm in Adrenal Incidentaloma Patients With Mild Autonomous Cortisol Secretion, J Clin Endocrinol Metab 2017; 102:3461-3469. DOI:10.1210/jc.2017-00823.
(25) Chiodini I, Viti R, Coletti F, et al. Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures. Clin Endocrinol (Oxf) 2004; 70:208-213. DOI:10.1111/j.1365-2265.2008.03310.x.
(26) Chiodini I, Guglielmi G, Battista C, et al. Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effect of subclinical hypercortisolism and gonadal status. J Clin Endocrinol Metab 2004; 89:2237-2241. DOI:10.1210/jc.2003-031413.
(27) Eller-Vainicher C, Morelli V, Salcuni AS, et al. Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma. Eur J Endocrinol 2010; 163:925-935. DOI:10.1530/EJE-10-0602.
(28) Petramala L, Olmati F, Concistrè A, et al. Cardiovascular and metabolic risk factors in patients with subclinical Cushing. Endocrine 2020; 70(1):150-163. DOI:10.1007/s12020-020-02297-2.
(29) Pogorzelski R, Toutounchi S, Ambroziak U, et al. Effectiveness of unilateral laparoscopic adrenalectomy in ACTH-independent hypercortisolaemia and subclinical Cushing's syndrome – a retrospective study on a large cohort. Endokrynol Pol 2018; 69(4):411-415. DOI:10.5603/EP.a2018.0039.
(30) Raffaelli M, De Crea C, D'Amato G, et al. Outcome of adrenalectomy for subclinical hypercortisolism and Cushing syndrome. Surgery 2017; 161(1):264-271. DOI:10.1016/j.surg.2016.07.042.
(31) Iacobone M, Citton M, Scarpa M, et al. Systematic review of surgical treatment of subclinical Cushing's syndrome. Br J Surg 2015; 102(4):318-330. DOI:10.1002/bjs.9742.
(32) Bernini G, Moretti A, Iacconi P, et al. Anthropometric, haemodynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur J Endocrinol 2003; 148:213-219. DOI:10.1530/eje.0.1480213.
(33) Midorikawa S, Sanada H, Hashimoto S, et al. The improvement of insulin resistance in patients with adrenal incidentalomas by surgical resection. Clin Endocrinol (Oxf) 2001; 54:797-804. DOI:10.1046/j.1365-2265.2001.01274.x.
(34) Castinetti F et al. Approach to the Patient Treated with Steroidogenesis Inhibitors, J Clin Endocrinol Metab 2021; 106(7):2114-2123. DOI:10.1210/clinem/dgab122.
(35) Terzolo M, Pia A, Alì A et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002; 87:998-1003. DOI:10.1210/jcem.87.3.8277.
(36) Paschou SA, Kandaraki E, Dimitropoulou F, et al. Subclinical Cushing's syndrome in patients with bilateral compared to unilateral adrenal incidentalomas: a systematic review and meta-analysis. Endocrine 2016; 51(2):225-35; DOI:10.1007/s12020-015-0776-6.
(37) Papierska L, Ćwikła J, Rabijewski M, et al. Bilateral adrenal incidentaloma with subclinical hypercortisolemia: indications for surgery. Pol Arch Med Wewn 2014; 124(7-8):387-394. DOI:10.20452/pamw.2347.
(38) Chiodini I, Albani A, Ambrogio AG, et al. Six controversial issues on subclinical Cushing's syndrome, Endocrine 2017; 56(2):262-266. DOI:10.1007/s12020-016-1017-3.
This work is licensed under a Creative Commons Attribution 4.0 International License.